Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.46 |
| ▸ | IDH1 | O75874 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 8/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15385129 | 0.97 | PTGES (0.47) | PTGESIDH1POLBHPGDMEN1 | |
| SCHEMBL3109449 | 0.90 | PTGES (0.54) | PTGESHPGDTHRBALDH1A1 | |
| SCHEMBL3100803 | 0.90 | PTGES (0.54) | PTGESHPGDTHRBALDH1A1 | |
| SCHEMBL3093498 | 0.89 | PTGES (0.51) | PTGESPOLBHPGDMEN1KMT2A | |
| SCHEMBL11894984 | 0.88 | PTGES (0.47) | PTGESMEN1KMT2ATP53MAPT | |
| SCHEMBL3111197 | 0.88 | PTGES (0.54) | PTGESHPGDTHRBALDH1A1 | |
| SCHEMBL3108313 | 0.88 | PTGES (0.43) | PTGESPOLBMEN1KMT2ATP53 | |
| SCHEMBL3098864 | 0.86 | ITK (0.45) | PTGESCNR2 | |
| SCHEMBL3106258 | 0.85 | PTGES (0.44) | PTGESPOLBHPGDMEN1KMT2A | |
| SCHEMBL3101879 | 0.85 | PTGES (0.47) | PTGESPOLBHPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218670-A1 | METHODS OF TREATING DISEASES CHARACTERISED BY VASOCONSTRICTION | GESYNTA PHARMA AB (SE) | 2022-07-14 | — | — | US | disclosed |
| US-20190038603-A1 | METHODS OF TREATING DISEASES CHARACTERISED BY VASOCONSTRICTION | GESYNTA PHARMA AB (SE) | 2019-02-07 | — | — | US | disclosed |
| US-8921405-B2 | Compounds | OREXO AB (SE) | 2014-12-30 | — | — | US | disclosed |
| US-8921405-B2 | Compounds | OREXO AB (SE) | 2014-12-30 | — | — | US | disclosed |
| EP-2403852-B1 | 2-AMINOBENZIMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-20130303571-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20130303571-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20120196897-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| US-20120196897-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| US-20100256188-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-07 | — | — | US | disclosed |
| US-20100256188-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-07 | — | — | US | disclosed |
| US-20100256188-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196897-A1 | NEW COMPOUNDS | MTX1, LTB4R, RDX | PTGES 307/4885IDH1 4746/4885POLB 2998/4885 |
| US-20220218670-A1 | METHODS OF TREATING DISEASES CHARACTERISED BY VASOCONSTRICTION | PTGIS, PTGIR, PTGER1 | PTGES 4/4885IDH1 2444/4885POLB 2995/4885 |
| US-20190038603-A1 | METHODS OF TREATING DISEASES CHARACTERISED BY VASOCONSTRICTION | PTGIS, PTGIR, PTGER1 | PTGES 4/4885IDH1 2444/4885POLB 2995/4885 |
| US-20130303571-A1 | NEW COMPOUNDS | MTX1, LTB4R, RDX | PTGES 307/4885IDH1 4746/4885POLB 2998/4885 |
| US-20100256188-A1 | NEW COMPOUNDS | MTX1, LTB4R, RDX | PTGES 307/4885IDH1 4746/4885POLB 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.